A biotech financing update that previews a company’s planned randomized clinical study testing an anti-Nogo-A therapy for acute spinal cord injury, useful for readers tracking emerging regenerative treatments.
Key Takeaways
- NovaGo secured CHF 24 million (USD 30 million) plus non-dilutive grants to fund clinical development
- Financing will enable a randomized, double-blind proof-of-concept trial enrolling 120 acute spinal cord injury patients
- Program targets Nogo-A with a fully human antibody intended to promote nerve outgrowth and functional recovery